Brady is a manufacturer and supplier of identification solutions and workplace safety products that identify and protect premises, products and people. The company is organized within two segments: Identification Solutions, which includes industrial and healthcare identification products in several categories, including facility identification and protection, product identification, wire identification, people identification, patient identification, and custom wristbands; and Workplace Safety, which includes workplace safety and compliance products in several categories, including safety and compliance signs, tags, and labels, informational signage, asset tracking labels, and first aid products.

Dova Pharmaceuticals is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The United States Food and Drug Administration has approved DOPTELET (avatrombopag), which is an orally administered thrombopoietin receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. The company is also conducting a trial in chemotherapy-induced thrombocytopenia.

Esperion Therapeutics is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The company's primary products, NEXLETOL? tablet and NEXLIZET? tablets, are oral, once-daily, non-statin LDL-C lowering medicines approved in the U.S. for patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). The U.S. Food and Drug Administration has approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C.

Hannon Armstrong Sustainable Infrastructure Capital focused on solutions that reduce carbon emissions and increase resilience to climate change by providing capital and capabilities to the companies in the energy efficiency, renewable energy and other sustainable infrastructure markets. The company focuses its investment activities primarily on: Behind-The-Meter, which includes distributed building or facility projects; Grid Connected, which projects deploy cleaner energy sources, such as solar and wind to generate power; and Other Sustainable Infrastructure, which includes upgraded transmission or distribution systems, water and storm water infrastructure, seismic retrofits and other projects.

Houston Wire & Cable is a holding company. Through its subsidiaries, the company is a provider of industrial products including electrical and mechanical wire and cable, industrial fasteners, hardware and related services. The company provides products in categories of wire and cable, including: continuous and interlocked armor cable; control and power cable; electronic wire and cable; flexible and portable cord; instrumentation and thermocouple cable; and premise and category wire and cable, primary and secondary aluminum distribution cable, steel wire rope and wire rope slings. The company also provides private branded products, including its proprietary brand LifeGuard, a low-smoke, zero-halogen cable.

International Flavors & Fragrances is a creator and manufacturer of taste, scent and complementary adjacent products, including cosmetic active and natural health ingredients. The company's operating segments are Taste and Scent. The Taste segment develops a range of different flavors and taste offerings for its customers, most of which are tailor-made. The company's Taste business is comprised of various portfolios across flavor compounds, savory solutions, inclusions and nutrition and specialty ingredients. The Scent segment creates fragrance compounds and fragrance ingredients for the household and personal care products. The company also produces cosmetic active and functional ingredients for use in cosmetics.

Krystal Biotech is a gene therapy company which is engaged in the developing and commercializing treatments for patients suffering from dermatological diseases. The company has developed a gene therapy platform, which it refers to as the Skin TARgeted Delivery platform, that consists of engineered, patented, viral vector based on herpes simplex virus 1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The company's primary candidate, KB103, a gene therapy product, is in preclinical development to treat dystrophic epidermolysis bullosa, a rare and severe genetic disease.

Lexicon Pharmaceuticals is a biopharmaceutical company. The company is commercializing XERMELO? (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. The company is developing Zynquista? (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 2 diabetes. The company is also developing sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease. The company is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

Raven Industries is a technology company providing a range of products to customers within the industrial, agricultural, geomembrane, construction, commercial lighter-than-air and aerospace/defense markets. The company has three reportable segments: Applied Technology Division, which includes application controls, GPS-guidance steering systems, field computers, automatic boom controls, information management tools, and injection systems; Engineered Films Division, which produces plastic films and sheeting for geomembrane, agricultural, construction, and industrial applications; Aerostar Division, which provides products that include high-altitude stratospheric balloons and radar systems.

Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. The company's main solar service offerings are provided through its lease and power purchase agreements, which it refers to as its Customer Agreements. While homeowners have the option to purchase a solar energy system outright from the company, a majority of its customers choose to buy solar as a service through its Customer Agreements. With its solar service offerings, the company installs solar energy systems on its customers' homes and provides them the solar power produced by those systems. In addition, the company monitors, maintains and insures the system during the term of the contract.